The Mesalamine suppositories will be manufactured at Zydus Lifesciences’ facility in Changodar, Ahmedabad, Gujarat. Shares of Zydus Lifesciences Ltd ended at ₹1,004.90, down by ₹4.10, or 0.41%, on the BSE.
The Mesalamine suppositories will be manufactured at Zydus Lifesciences’ facility in Changodar, Ahmedabad, Gujarat. Shares of Zydus Lifesciences Ltd ended at ₹1,004.90, down by ₹4.10, or 0.41%, on the BSE.